Add to ORKGThe US is using free trade agreements to address the global free rider problem in pharmaceutical R&D. This brief article outlines several objections to that approach
Approximately half of American consumers take at least one prescription drug a day. However, the Uni...
This paper begins by considering one corner of United States (U.S.) international trade policy; that...
The Free Trade Agreement of the Americas: Is free trade possible in the post-Seattle world? The Worl...
The Australia-U.S. Free Trade Agreement (AUSFTA), which entered into force on January 1, 2005, conta...
Providing access to affordable medicines and rewarding innovation produces a difficult tension in th...
Much of the rhetoric that underpins arguments for free trade relies on the assertion that free tra...
While neoclassical economic theory suggests that arbitrage will undermine global differential pricin...
In 2017 the United States Supreme Court adopted a regime of international exhaustion of U.S. patent ...
The Council of Economic Advisers to the President of the United States in its 2018 report sought to ...
In December 2005, the WTO responded to the HIV/AIDS pharmaceutical crisis in the least developed wor...
In January 2005 Australia implemented the Australia? United States Free Trade Agreement (AUSFTA). Th...
The objective for this article is to understand the legitimacy and limitations of US involvement in ...
Objective: The debate on the extent intellectual property protection should be used to reward innova...
A little-noticed provision of the Australia-US Free Trade Agreement could prove to be a nasty surpri...
This article discusses the recent passage of the Medicare Prescription Drug, Modernization and Impro...
Approximately half of American consumers take at least one prescription drug a day. However, the Uni...
This paper begins by considering one corner of United States (U.S.) international trade policy; that...
The Free Trade Agreement of the Americas: Is free trade possible in the post-Seattle world? The Worl...
The Australia-U.S. Free Trade Agreement (AUSFTA), which entered into force on January 1, 2005, conta...
Providing access to affordable medicines and rewarding innovation produces a difficult tension in th...
Much of the rhetoric that underpins arguments for free trade relies on the assertion that free tra...
While neoclassical economic theory suggests that arbitrage will undermine global differential pricin...
In 2017 the United States Supreme Court adopted a regime of international exhaustion of U.S. patent ...
The Council of Economic Advisers to the President of the United States in its 2018 report sought to ...
In December 2005, the WTO responded to the HIV/AIDS pharmaceutical crisis in the least developed wor...
In January 2005 Australia implemented the Australia? United States Free Trade Agreement (AUSFTA). Th...
The objective for this article is to understand the legitimacy and limitations of US involvement in ...
Objective: The debate on the extent intellectual property protection should be used to reward innova...
A little-noticed provision of the Australia-US Free Trade Agreement could prove to be a nasty surpri...
This article discusses the recent passage of the Medicare Prescription Drug, Modernization and Impro...
Approximately half of American consumers take at least one prescription drug a day. However, the Uni...
This paper begins by considering one corner of United States (U.S.) international trade policy; that...
The Free Trade Agreement of the Americas: Is free trade possible in the post-Seattle world? The Worl...